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Approximately one third or 75 million adults in the US have idiopathic hypertension,1 
also known as essential hypertension (HTN). Hypertension, a common cause of kidney disease, 
is also a known cause of heart disease and stroke, both of which are leading causes of death in 
the United States.2  Therefore, controlling hypertension is vital for prevention of complications, 
which can make it challenging to treat due to patient compliance issues. Nonetheless, long-term 
control of blood pressure decreases adverse cardiovascular, cerebrovascular and renal outcomes. 
According to the American College of Cardiology (ACC) and the American Heart Association 
(AHA) define stages of hypertension, Stage 1 (systolic: 130-139 mm Hg or diastolic: 80-89 mm 
Hg) and Stage 2 (systolic ≥140 mm Hg or diastolic ≥90 mm Hg) as shown in Table 1.3 The JNC 
8 treatment guidelines recommend a target blood pressure of less than 130/80mmHg. Beyond 
lifestyle management, many medications are available to treat hypertension and, thus, lower the 
risk of long-term complications. First line therapy for essential hypertension includes four 
classes of drugs: calcium channel blockers (CCBs), thiazide diuretics, angiotensin converting 
enzyme inhibitors and angiotensin type 2 receptor blockers,4 see figure 1 for mechanisms of 
action.5 Two well-known and widely used treatment options are Angiotensin Converting Enzyme 
Inhibitors, or ACE inhibitors, and Angiotensin II Receptor Blockers, also known as ARBs.  
Historically, these medications have been used interchangeably, often initiating therapy with an 
ACE inhibitor and switching to an ARB if the patient does not tolerate the ACE inhibitor. As 
most providers know, ACE inhibitors are associated with increased risk of cough and 
angioedema when compared to ARBs.6,7  When compared to ACE inhibitors, ARBs are more 
selective and potentially exert more complete blockade of angiotensin II. This is due to blockade 
 
2 
of other enzymes apart from ACE which produce angiotensin and their lack of effect on 
bradykinin, unlike ACE-inhibitors.5 
 However, many studies have confirmed that both exert equivocal control on blood 
pressure.6,8,9  Currently, another factor that affects choice of prescription is the higher cost 
associated with ARBs compared to ACE inhibitors. Nonetheless, cost is becoming less of an 
issue due to generic availability of most medications in each class. If cost is no longer a barrier, 
then determining whether an ACEI or an ARB is superior in preventing long-term complications 
will change clinical practice. 
blood volume 







Calcium Channel Blockers (CCB): inhibits Ca2+ into the arterial smooth muscle resulting in 
peripheral vasodilation and decreased cardiac contractility  
Thiazide Diuretics: Inhibits Na+/Cl- transporter in the distal convoluted tubule resulting in increased 
Na+ and H2O excretion 
Angiotensin Converting Enzyme Inhibitors (ACE-I): prevent conversion of angiotensin I to 
angiotensin II resulting in peripheral vasodilation and inhibition of aldosterone secretion 
Angiotensin Type 2 Receptor Blockers (ARB): block angiotensin II resulting in peripheral 
vasodilation and inhibition of aldosterone secretion 
 





This review examines the relevant question: in adult patients with idiopathic hypertension 
how does Angiotensin II Receptor Blocker therapy compare to Angiotensin Converting Enzyme 
Inhibitor therapy for prevention of adverse cardiovascular, renal or cerebrovascular outcomes? 
BP Class Systolic (mmHg)  Diastolic (mmHg) 
Normal <120 And <80 
Elevated 120-129 And <80 
Stage 1 HTN 130-139 Or 80-89 
Stage 2 HTN >140 Or >90 
 
Discussion 
 Medical evidence to date confirms that ACE inhibitors and ARBs provide equivalent 
blood pressure control6,8,9. However, for prevention of specific outcomes, the data show stronger 
support for ACE inhibitors than ARBs, and vice-versa. Nonetheless, there is no clear answer as 
to whether one of these drugs has overall superiority for prevention of long-term complications 
of hypertension.  
Data in Favor of ACE inhibitors 
 ACE inhibitors are superior to ARBs for reducing morbidity and mortality from 
myocardial infarction when treating hypertension in type 2 diabetics and other high-risk 
populations, as was shown in a meta-analysis of placebo-controlled trials published in 201810. 
 Table 1: AHA/ ACC HTN classification, adapted from American College of Cardiology/ 
American Heart Association Task Force on Clinical Practice Guidelines DETAILED 
SUMMARY FROM THE 2017 Guideline for the Prevention, Detection, Evaluation and 
Management of High Blood Pressure in Adults3 
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This article discusses the ARB-MI paradox, which refers to the risk reduction of myocardial 
infarction (MI) and mortality seen with ACE inhibitors, not with ARBs10.  The data are 
compelling because of the recency of the publication, the large sample size (n=128,680) and the 
convincing findings. However, the population was limited to patients with comorbidities or 
patients at high risk for cardiovascular events, and thus, does not directly answer whether ACE 
inhibitors are better in patients with hypertension without significant comorbid conditions.  
Additional research found secondary prevention/ risk reduction with ACE inhibitors for non-fatal 
MI, CV mortality and all-cause mortality.11,7 In a meta-analysis of RCTs, Hoang et al analyzed 
the efficacy of ACE inhibitors versus ARBs for CV event reduction in patients with CAD 
without heart failure in the context of statin therapy. These findings support the hypothesis of 
ACE inhibitor’s superiority in prevention of adverse cardiovascular events. The sample size was 
large (n=78,761) and the research is up-to-date, however, the article did not provide data on the 
dose or potency of concurrent statin therapy. Hence, it is difficult to extrapolate whether the 
cardiovascular risk reduction was secondary to statin therapy, ACE inhibitor therapy, a 
combination of the two or other components of coronary artery disease treatment. In 2018, 
Messerli et al conducted a literature review comparing outcomes and adverse events between 
ACE inhibitors and ARBs in patients with hypertension. Their review yielded equivalent 
outcomes for both groups except in patients with comorbid coronary artery disease, in which 
ACE inhibitors, once again, were found to be superior. 
 For adverse cerebrovascular outcomes, such as stroke (cerebrovascular accident or CVA), 
similar risk reductions were found by Hoang et al when hypertension was treated in patients with 
coronary artery disease but without heart failure11. This meta-analysis provides intriguing 
evidence. The sample was very inclusive; subjects included patients with a combination of 
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coronary artery disease risk factors (hypertension, dyslipidemia, diabetes or previous 
atheromatous conditions). Although the findings from this meta-analysis may not be exclusive to 
patients with isolated idiopathic hypertension, they may be even more compelling, given the 
variety of conditions treated and the lack of difference between ACE inhibitors and ARBs for 
cerebrovascular outcomes. However, as stated above, it is difficult to isolate Renin-Angiotensin-
Aldosterone System (RAAS) blockade as the cause of cerebrovascular risk reduction due to the 
concurrent statin therapy. 
Data in favor of ARBs 
 Although, ACE inhibitors and ARBs have been shown to have equivalent blood pressure 
control, azilsartan medoxomil had superior blood pressure reduction and lower discontinuation 
rates when compared to ramipril. This investigation was one of the few current randomized, 
controlled, double-blind trials comparing an ACE inhibitor and an ARB head-to-head8. 
Furthermore, the data was gathered from a large sample size (n=784) from patients at different 
sites throughout Europe and Asia. However, the sample only included patients with a recorded 
clinic systolic blood pressures of 150-180mm Hg.  
 Although, multiple sources have shown superior stroke risk reduction with ACE 
inhibitors, the 2016 retrospective cohort study on patients with hypertension and diabetes in 
Taiwan showed that ARBs provide a 35% higher reduction in ischemic stroke than ACE 
inhibitors, ACE inhibitors combined with ARBs, or neither12. Although these data were not 
derived from a randomized controlled trial, their significance still warrants further evaluation. 
The investigation extracted data from Taiwan’s health insurance claims on all patients 18 years 
and older diagnosed with hypertension from 1997 to 2010. Limitations of this study included the 
distinct population studied, which may have had lifestyles, exposures, or genetic risk factors for 
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CVA that are different from other populations. The data also lacked measurement of medication 
non-compliance. Strengths of this article include its large sample size and the lengthy time 
period from which the data were collected, which distinguishes it from much of the literature 
available for analysis. It is also important to note that the data excluded patients who had pre-
existing cardiovascular disease or arrhythmias.  
 Overall, according to the Cochrane (systematic) Review published in 2014, ARBs are 
non-inferior, based on moderate-quality evidence, to ACE inhibitors for total mortality in the 
treatment of essential hypertension13. This review questioned whether ACE inhibitors were 
superior to ARBs for preventing mortality, cardiovascular events and withdrawal due to adverse 
events. The sample included 11,007 subjects with uncontrolled or controlled essential 
hypertension with or without risk factors. 
Conclusion 
 According to the evidence in current medical literature, prevention of adverse 
cardiovascular, renal and cerebrovascular events in patients with idiopathic hypertension appears 
to depend on the patient’s comorbid conditions. Data suggests ACE inhibitors are superior for 
prevention of adverse cardiovascular events, particularly non-fatal myocardial infarction, 
cardiovascular mortality and all-cause mortality, in high risk populations such as patients with 
type 2 diabetes or coronary artery disease without heart failure7,10,11.  The evidence is conflicting 
on the topic of cerebrovascular risk reduction.  Both ACE-inhibitors and ARBs reduced the risk 
of stroke in pts with HTN and CAD11.  However, one article reflects superiority of ARBs to ACE 
inhibitors12.  The data as a whole is lacking assessments for the prevention of adverse renal 
events; this potential adverse outcome is an important area for data collection given that 
hypertension is one of the main causes of chronic kidney disease. Direct head-to-head 
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comparison of ACE inhibitors to ARBs in patients with isolated idiopathic hypertension are 
lacking as well, which Strauss pointed out10. There are several barriers to further research on this 
topic. For example, research comparing drug classes as a whole are unlikely to be funded by 
pharmaceutical industries because these drugs are already available in generic formulations.  
Moreover, research in academia may be constrained by limited funds.   For better analysis of 
long-term risk reduction in treatment of hypertension a randomized-controlled trial must be 
conducted to accurately compare ACE inhibitors to ARBs, possibly with placebo control if 
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